Methodological Study to Compare the Effect of Different Methods of Measuring Cat Allergy Symptoms in Patients That Have Immunized Their Cats With FEL-CMV.

Hypersensitivity Clinical Trial

Official title:

Methodological Study to Compare the Effect of Different Methods of Measuring Cat Allergy Symptoms in Patients That Have Immunized Their Cats With FEL-CMV.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03089788
• Other study ID #: ZU-HypoCat-002
• Status: Completed
• Phase: N/A
• First received: March 17, 2017
• Last updated: March 19, 2018
• Start date: March 30, 2017
• Est. completion date: March 19, 2018

Study information

• Verified date: March 2018
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this Project we will monitor the symptoms of cat allergic participants who live together with a cat which is immunized with FEL-CMV using the novel symptom recording method "HypoScore", a General weekly symptom score, and a skin prick test before and after immunization of the cat. This project may enable us to determine if the scoring System and the tests are able to detect a difference in participant symptoms before and after immunization of the cats.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 19, 2018
• Est. primary completion date: February 13, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Signed informed consent after participants' information

• 18 to 65 years, male or female

• Participant understands the nature, meaning and scope of the study

• Positive screening prick test (wheal diameter = 3mm) to Histamine dihydrochloride 10mg/ml

• Positive screening prick test (mean wheal diameter = 3 mm) when tested with already standardized cat allergen extract

• Positive screening scratch test when tested with cat dander sample of participant's cat.

• Living with a cat in the same household and parallel participation in the cat study in which the cat will be immunized

• A positive clinical history with inhalant allergy presumably due to cat allergen

Exclusion Criteria:

• Immunosuppression or haematological diseases, in particular anaemias or leukaemia

• Other previous or current condition or participation in clinical trials influencing the results of the present study by discretion of the investigator

• Incapable of understanding the nature, meaning or scope of the research project or incapable of giving written informed consent

• Unwilling or incapable of following the study procedures, e.g. due to language problems, psychological disorders, dementia, known or suspected drug or alcohol abuse etc.

• Women who are pregnant or breast feeding or having the intention to become pregnant during the course of the study

• Positive skin reaction in the screening prick test to negative control

• History of anaphylactic reaction to pet allergens

• Severe diseases influencing the results of the present study by discretion of the investigator

• Immunotherapy with Fel d 1 / cat allergen preparation during the past two years.

• Skin lesions and excessive hair growth in the skin test areas

• Treatment with prohibited concomitant medications with the exception of medications with local effects which will not influence the results of the skin tests and the results of the other tests (testing period)

• The participant should not suffer from other respiratory allergies during this study (people who suffer from asthma are not excluded)

Related Conditions & MeSH terms

• Hypersensitivity

Intervention

Other:
• Home-based test
Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
• Skin test
Skin Prick Tests will be performed with registered cat allergen extract.

Locations

Country	Name	City	State
Switzerland	University Hospital Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Organ specific symptom sum score of HypoScore measured after petting the cat at baseline versus week 24	Organ specific symtpom score component of HypoScore is measured with a questionnaire before and after the participants perform the tests with their cats (petting the cat until certain symptoms are reached).	Comparison of the symptom score of 3 baseline measurements and measurement in week 24
Primary	General weekly symptom score measured at baseline (with unimmunized cat) versus week 24 (with immunized cat)	General weekly symptom score is measured with a weekly questionnaire. This questionnaire will be filled in on a weekly Basis.	Measured over 25 weeks